by | Oct 22, 2019 | Chen, Hong, Dunn, Gavin, Leuthardt, Eric, Petti, Allegra
— Background: The American Brain Tumor Association reports that about 80,000 of the estimated 700,000 Americans that live with a brain tumor have been diagnosed in 2017. The surgery required for a traditional brain tumor biopsy entails making a hole in the skin and skull, placing a needle probe, and r…
by | Oct 22, 2019 | Guruswami, Sundaram, Sharma, Vijay, Sivapackiam, Jothilingam
— Background
Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
by | Oct 22, 2019 | Berezin, Mikhail, Binkley, Michael, Meacham, John
— Technology Description:
Methods and devices used for acoustophoresis of biologics have been developed and allow for more than 10,000 fold throughput than existing acoustophoretic devices.
Applications:
1. Isolation of cells in low abundance (immune cells, circulating tumor cells) from whole bloo…
by | Jul 31, 2018 | Tobin, Garry
— Technology Description: A hospital-based algorithm and associated software that is able to predict which in-patients on diabetic therapy will develop hypoglycemia. It is able to predict in real time which patients are at risk and alert MDs to start interventions to prevent possible side effects or d…
by | Jun 7, 2018 | Shaikh, Nurmohammad, Tarr, Phillip
— Primary Inventor: Phillip I. Tarr, MD
Target: GelE(mAb 8A3)
Monoclonal antibodies against E. faecalis gelatinase developed as a treatment for Crohn’s disease. E. faecalis secretes many proteins into the gastrointestinal enviroment – such as Gelatinase (GelE). GelE degrades several proteins including gelatin, collagin, hemoglobin, and bioactive peptides.…